CEP-6800

• Description:

  CEP-6800 is an inhibitor of PARP-1 with chemopotentiating ability. CEP-6800 attenuates irinotecan (HY-16562) - and Temozolomide (HY-17364) -induced poly (ADP-ribose) accumulation in LoVo as well as HT29 xenografts. CEP-6800 can suppress Calu-6 tumor growth. CEP-6800 can be studied in anti-cancer research[1].

• UNSPSC:

  12352005

• Target:

  PARP

• Related Pathways:

  Cell Cycle/DNA Damage; Epigenetics

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Smiles:

  O=C1NC(C2=C1C3=C(C4=C2CCC4)NC5=C3C=C(CN)C=C5)=O

• Molecular Formula:

  C18H15N3O2

• Molecular Weight:

  305.33

• References & Citations:

  [1]Miknyoczki, S. J., et al., (2003) . Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly (ADP-ribose) polymerase inhibitor. Molecular cancer therapeutics, 2 (4), 371-382.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [609848-02-4]